Skip to main content

Table 2 Observed mean changes by visit month and treatment group for primary endpoints, ALT and HBa

From: The effect of standard dose multivitamin supplementation on disease progression in HIV-infected adults initiating HAART: a randomized double blind placebo-controlled trial in Uganda

End point Multivitamin Placebo Two-sided p-value for change over timeb
- n - Mean (SD) - n - Mean (SD)
Change in CD4 (cells/uL)
 0–3 months 194 77 (97) 193 86 (103) 0.726
 0–6 months 191 74 (95) 190 94 (92)  
 0–12 months 183 106 (112) 188 117 (116)  
 0–18 months 181 141 (160) 186 147 (130)  
Change in weight (kg)
 0–3 months 194 1.2 (2.9) 195 1.2 (3.3) 0.691
 0–6 months 191 2.1 (4.2) 190 1.7 (4.0)  
 0–12 months 183 3.2 (5.4) 188 3.1 (5.0)  
 0–18 months 181 3.9 (6.2) 187 3.3 (5.8)  
Change in QoL score
 0–6 months 191 6.1 (11.1) 190 7.5 (12.7) 0.454
 0–12 months 181 8.1 (10.9) 187 8.4 (12.0)  
 0–18 months 181 6.8 (12.4) 186 8.8 (12.4)  
Change in ALT (IU/I)
 0–6 months 190 0.99 (32.8) 188 −2.78 (20.9)  
 0–12 months 183 0.56 (41.5) 187 −1.66 (22.1) 0.064
 0–18 months 180 −1.69 (33.4) 186 −0.02 (30.0)  
Change in HB (g/dL)
 0–6 months 191 0.68 (1.6) 190 0.60 (1.5)  
 0–12 months 183 0.92 (1.4) 188 0.81 (1.6) 0.977
 0–18 months 181 1.01 (1.5) 186 0.91 (1.7)  
  1. aALT Alanine transaminase, HB Hemoglobin, Q1 Upper limit of first quartile, Q3 Upper limit of third quartile
  2. bBased on linear mixed effects model analysis adjusting for age and baseline value